International Prostate Symptom Score

Seoul St. Mary's Hospital Found Red Ginseng Oil is Excellent for Improving Prostatic Hyperplasia

Retrieved on: 
Thursday, September 14, 2023

SEOUL, South Korea, Sept. 14, 2023 /PRNewswire/ -- Red ginseng oil has been found to be a safe and effective solution for improving prostatic hyperplasia for the first time.

Key Points: 
  • SEOUL, South Korea, Sept. 14, 2023 /PRNewswire/ -- Red ginseng oil has been found to be a safe and effective solution for improving prostatic hyperplasia for the first time.
  • Led by Professor Kim Sae Woong from the Department of Urology at Seoul St. Mary's Hospital, in collaboration with the Korea Ginseng Corporation (KGC), this research's results indicate that the intake of red ginseng oil extracted from JUNG KWAN JANG's RXGIN can safely and effectively improve prostatic hyperplasia.
  • It turns out that, compared to a mere 3.7% improvement in the control group, the red ginseng oil group experienced a significant 50.5% improvement in the red ginseng oil group in IPSS.
  • Professor Kim explained, "We found that red ginseng oil not only significantly improves the symptoms of BPH but also enhances dysfunction, which are the side effects of existing BPH(Benign prostatic hyperplasia) treatments."

New Data Highlight that Early Intervention with the UroLift® System Facilitates Long-Term Outcomes for BPH Patients

Retrieved on: 
Wednesday, May 3, 2023

PUL with the UroLift® System was durable in most subjects at one and five years.

Key Points: 
  • PUL with the UroLift® System was durable in most subjects at one and five years.
  • In surgical therapy patients, procedure complication rates were lowest for the UroLift® System (17%) and highest for Rezūm™ (28%).
  • “As clinicians listen to their patients’ goals, technological advances are allowing them to deliver treatments that reflect those priorities better than ever before.
  • The data presented at AUA reinforce the importance of earlier intervention in BPH and the UroLift® System as an effective and durable BPH solution that improves patients’ quality of life and supports a superior patient experience.”1-3

Urotronic Announces Presentation of Data from Two Clinical Trials Evaluating Optilume® BPH System's Effectiveness and Durability

Retrieved on: 
Monday, May 1, 2023

MINNEAPOLIS, May 1, 2023 /PRNewswire/ -- Urotronic, Inc., a Minnesota-based medical device company pioneering the application of its drug-coated balloon technology for use in interventional urology, today announced the presentation of positive data from two clinical trials evaluating the Optilume® BPH System's effectiveness and durability in treating lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Four-year and 12-month data from the EVEREST and PINNACLE clinical trials were presented by Dr. Steven A. Kaplan, professor of urology at the Icahn School of Medicine at Mount Sinai in New York and the principal investigator of the two studies, during the American Urological Association's (AUA) Annual Meeting in Chicago.

Key Points: 
  • "The positive data from the PINNACLE and EVEREST trials – including the highest reported Qmax in BPH MIST trials to date – demonstrates clear and compelling sustained clinical outcomes through four years post-treatment," said Dr. Kaplan.
  • "Optilume BPH is not your grandfather's BPH balloon – it's the next generation of minimally invasive technology, creating a new drug device space among BPH therapies."
  • Mechanical dilation with Optilume BPH achieves an anterior commissurotomy, while delivery of paclitaxel is intended to maintain luminal patency during healing.
  • The highest average peak urinary flow rate (Qmax) at 12 months reported in randomized MIST trials for BPH.

UroLift® System Research Data from EAU Highlight Durability and Superior Patient Experience, Along with Benefits of Earlier Treatment for BPH

Retrieved on: 
Monday, March 13, 2023

WAYNE, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced new research from controlled and real-world studies of the Prostatic Urethral Lift (PUL) procedure with the UroLift® System, for treating men with benign prostatic hyperplasia (BPH). Results underscore the benefits of early intervention with respect to durability, symptom improvement and sexual function that urologists around the world have come to expect from the UroLift® System, which is the leading minimally invasive, outpatient treatment in the United States for enlarged prostate.1 The research was presented at the 38th Annual European Association of Urology (EAU) Congress taking place in Milan from March 10-13, 2023.

Key Points: 
  • “These important new analyses show that, whether compared to other interventions or medication, the UroLift® System offers unique benefits that make it the treatment of choice for many men searching for long-term relief of burdensome BPH symptoms,” said Jacqueline Welch, Vice President, Global Clinical and Scientific Operations, Teleflex.
  • Following are key findings from the studies:
    PUL with the UroLift® System was durable in most subjects at one and five years.
  • Additionally, only these TURP subjects experienced high-severity adverse events.4
    Outcomes from the largest healthcare utilization study for BPH therapies, including medication5
    Procedure complication rates were similar between TURP, Photoselective Vaporization of the Prostate (PVP) and Aquablation®, and lowest for PUL with the UroLift® System.
  • “The results from these studies emphasize the value of the UroLift® System in successfully treating BPH symptoms, enabling rapid recovery, preserving sexual function, and improving patients’ overall quality of life.”2-5

Global High Intensity Focused Ultrasound Market (2022 to 2027) - Featuring Hitachi, General Electric and Medtronic Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 16, 2022

Besides, focused ultrasound surgery (FUS) is a non-invasive technique that can ablate tumor lesions precisely when combined with high-intensity imaging methods.

Key Points: 
  • Besides, focused ultrasound surgery (FUS) is a non-invasive technique that can ablate tumor lesions precisely when combined with high-intensity imaging methods.
  • As the COVID-19 pandemic progresses, the High-intensity focused ultrasound (HIFU) therapy industry has seen a growth drop.
  • Worldwide High-intensity Focused Ultrasound (HIFU) Therapy Market Size was US$ 269.3 Million in 2021:
    Based on modality, the High-Intensity Focused Ultrasound Therapy market is segmented into therapeutic ultrasound, hemostasis, others.
  • Major players operating in the HIFU therapy industry include Johnson & Johnson, Hitachi, Ltd, General Electric, Medtronic, Inc., Stryker, Koninklijke Philips, EDAP TMS S.A, Supersonic Imagine.

Study Results Show Long-term Efficacy of iTind Procedure

Retrieved on: 
Wednesday, May 18, 2022

CENTER VALLEY, Pa. and HAMBURG, Germany, May 18, 2022 /PRNewswire/ -- Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today the summary results of a follow-up study to measure the durability of the iTind™ procedure for treating the lower urinary tract symptoms caused by BPH (benign prostatic hyperplasia). The abstract was presented at the American Urological Association Annual Meeting (AUA) on May 15, 2022.1

Key Points: 
  • "The data demonstrate that the iTind procedure is a safe and effective treatment for BPH symptoms that is durable over time."
  • "These study results are highly anticipated by urologists, which was confirmed by the high interest in the iTind device at the Olympus booth at the 2022 AUA meeting," said Vanessa Malka, Executive Director and iTind Commercial Head for Olympus Corporation.
  • "The results demonstrate that the iTind procedure is an alternative to current BPH therapies.
  • More information about the iTind procedure in the U.S. is available at BPHTherapy.com/iTind and in the EMEA region at olympus-europa.com/medical/en/Products-and-Solutions/Products/Product/iTind.html .

Study Results Show Long-term Efficacy of iTind Procedure

Retrieved on: 
Wednesday, May 18, 2022

CENTER VALLEY, Pa. and HAMBURG, Germany, May 18, 2022 /PRNewswire/ -- Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today the summary results of a follow-up study to measure the durability of the iTind™ procedure for treating the lower urinary tract symptoms caused by BPH (benign prostatic hyperplasia). The abstract was presented at the American Urological Association Annual Meeting (AUA) on May 15, 2022.1

Key Points: 
  • "The data demonstrate that the iTind procedure is a safe and effective treatment for BPH symptoms that is durable over time."
  • "These study results are highly anticipated by urologists, which was confirmed by the high interest in the iTind device at the Olympus booth at the 2022 AUA meeting," said Vanessa Malka, Executive Director and iTind Commercial Head for Olympus Corporation.
  • "The results demonstrate that the iTind procedure is an alternative to current BPH therapies.
  • More information about the iTind procedure in the U.S. is available at BPHTherapy.com/iTind and in the EMEA region at olympus-europa.com/medical/en/Products-and-Solutions/Products/Product/iTind.html .

Novel Review Reveals Global Body of Evidence for Effectiveness of Standardized Saw Palmetto Extract for Aging Men

Retrieved on: 
Tuesday, January 18, 2022

A high-quality saw palmetto extract is one that meets the standardized profile set by agencies like the European Medicines Agency (EMA) or the United States Pharmacopeia (USP).

Key Points: 
  • A high-quality saw palmetto extract is one that meets the standardized profile set by agencies like the European Medicines Agency (EMA) or the United States Pharmacopeia (USP).
  • Among the 58 evaluable studies reviewed, 55 studies confirmed a benefit that came with the use of saw palmetto extract.
  • The review highlighted that crushed dried saw palmetto berry powder, the predominant preparation available in the USA, is not comparable to the clinically effective dose of 320 mg/day lipidosterolic extract of saw palmetto.
  • The evidence from this comprehensive global review suggests that a standardized saw palmetto extract can be another beneficial tool for these patients.

Zenflow Launches Pivotal Clinical Trial of Minimally Invasive Spring® Treatment for Enlarged Prostate Symptoms

Retrieved on: 
Monday, October 4, 2021

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zenflow, Inc. , a medical device company developing a minimally invasive treatment for enlarged prostate, or benign prostatic hyperplasia (BPH), has initiated the BREEZE pivotal clinical trial to evaluate its Spring System.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zenflow, Inc. , a medical device company developing a minimally invasive treatment for enlarged prostate, or benign prostatic hyperplasia (BPH), has initiated the BREEZE pivotal clinical trial to evaluate its Spring System.
  • The symptoms associated with enlarged prostate have a substantial impact on patients quality of life, said Dr. Roehrborn.
  • I am encouraged by the potential for the Spring treatment to improve the patient experience and am proud to be part of this rigorous clinical trial program.
  • The BREEZE trial is a prospective, multicenter, controlled study in patients with lower urinary tract symptoms due to enlarged prostate.

Prodeon Medical Announces Presentation of Interim Results from its EXPANDER-1 Multicenter Clinical Trial for its Urocross™ Expander System for Symptoms related to Benign Prostatic Hyperplasia

Retrieved on: 
Thursday, September 16, 2021

Prof Woo stated, "Based on these early results, we are thrilled that the primary clinical objective of the feasibility and safety study have been positive."

Key Points: 
  • Prof Woo stated, "Based on these early results, we are thrilled that the primary clinical objective of the feasibility and safety study have been positive."
  • Preliminary results from 39 patients treated in this study demonstrate that the procedure using the Urocross Expander System is feasible and safe with no reported procedural complications.
  • The Urocross Expander System consists of two primary components: the Urocross Delivery System and the preloaded Urocross Expander Implant.
  • The Prodeon Medical initiative was started in 2016 with the mission of rethinking the treatment of the lower urinary tract symptoms due to Benign Prostatic Hyperplasia (BPH).